Plant Name: Xanthium strumarium
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; HCAR2; | |
| PTPN1; | |
| GAA; | |
| TDP1; FAAH; TERT; HPGD; AKR1B1; GFER; HSD17B10; AKR1B10; ALOX15; ALDH1A1; APEX1; POLB; | |
| AKT1; | |
| CA2; CA12; CA1; CA9; CA7; CA14; CA5B; CA5A; CA4; CA6; CA3; | |
| PPARA; PPARD; PPARG; | |
| ESR1; ESR2; | |
| KDM4E; | |
| CASP1; CASP7; | |
| MMP1; MMP2; MMP9; | |
| TLR2; | |
| HIF1A; TP53; NFKB1; | |
| HTT; RAB9A; LMNA; FABP3; FABP5; FABP2; FABP4; MCL1; MAPT; APP; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.256E-09 | 1.013E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.620E-08 | 2.288E-05 | AKR1B1, AKR1B10, APP, CYP1A2, CYP2C19, CYP2C9, CYP2D6, ESR1, PPARD |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 5.900E-07 | 1.548E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 8.331E-07 | 2.038E-04 | AKT1, HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.013E-06 | 2.372E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.629E-06 | 3.477E-04 | AKT1, MAPT, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.367E-06 | 6.109E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.906E-06 | 8.757E-04 | AKT1, FABP3, FFAR1, PPARG, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.328E-25 | 2.892E-21 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.145E-06 | 1.045E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.145E-06 | 1.045E-03 | CYP1A2, CYP2C9, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.488E-06 | 1.508E-03 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.488E-06 | 1.508E-03 | ESR1, ESR2 |
| BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 1.001E-05 | 1.580E-03 | AKT1, APP, ESR1, ESR2, NFKB1, PPARG, TLR2 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.139E-05 | 1.738E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.141E-05 | 1.738E-03 | AKT1, HIF1A, MCL1, MMP9, PTPN1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.139E-05 | 1.738E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6 |
| BP | Unclassified; | GO:1905953; negative regulation of lipid localization | 1.358E-05 | 1.997E-03 | AKT1, NFKB1, PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 2.129E-05 | 3.010E-03 | AKR1B1, AKT1, APEX1, MMP9, TP53 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 2.249E-05 | 3.139E-03 | AKT1, HIF1A, TERT |
| BP | GO:0009987; cellular process | GO:1901214; regulation of neuron death | 2.387E-05 | 3.311E-03 | AKT1, HIF1A, MAPT, MCL1, PPARA, TERT, TP53 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 2.555E-05 | 3.473E-03 | AKR1B1, ALDH1A1, ESR1, FFAR1, FFAR4, HCAR2, HIF1A, NFKB1, PPARD |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.568E-05 | 3.473E-03 | AKT1, APP, CASP1, ESR1, ESR2, HPGD, HTT, L3MBTL1, MAPT, MCL1, MMP9, NFKB1, PPARG, RAB9A, TERT, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 2.841E-05 | 3.704E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.841E-05 | 3.704E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.883E-05 | 3.736E-03 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 3.128E-05 | 4.031E-03 | ESR1, PPARA, TERT |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.642E-05 | 4.480E-03 | POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.642E-05 | 4.480E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 3.944E-05 | 4.824E-03 | AKR1B1, AKT1, ALOX15, APP, CASP1, FFAR4, HTT, MCL1, PPARD, PTPN1, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 4.207E-05 | 5.034E-03 | HIF1A, TERT, TP53 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 4.949E-05 | 5.857E-03 | AKT1, APP, CYP2D6, ESR1, FABP4, MAPT, MMP9, NFKB1, PPARA, PPARG, PTPN1, RAB9A, TP53 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.189E-05 | 6.107E-03 | ESR1, ESR2, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 5.570E-05 | 6.397E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 5.670E-05 | 6.397E-03 | APP, TLR2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.670E-05 | 6.397E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.670E-05 | 6.397E-03 | CYP1A2, CYP2C9 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 5.892E-05 | 6.593E-03 | AKT1, CA2, CYP1A2, ESR1, GFER, HIF1A, HPGD, HTT, L3MBTL1, POLB, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 5.904E-05 | 6.593E-03 | AKT1, HIF1A, NFKB1, PPARA |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 6.242E-05 | 6.900E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 7.135E-05 | 7.768E-03 | AKT1, FABP3, PPARA, PPARG, TLR2 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 8.797E-05 | 9.474E-03 | CASP1, FFAR1, HCAR2, HIF1A, PPARD, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 9.003E-05 | 9.483E-03 | APEX1, APP, CASP1, PPARG, TP53 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 9.432E-05 | 9.780E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 9.609E-05 | 9.823E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.975E-19 | 5.063E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.067E-18 | 3.850E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.679E-14 | 4.062E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, L3MBTL1, MMP1, MMP2, MMP9, PPARA, PPARD, PPARG, PTPN1, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; HCAR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; TLR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; AKT1; TP53; CA9; TLR2; MMP2; MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; PPARD; NFKB1; HCAR2; PPARG; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; AKT1; CA9 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; MMP1; AKR1B1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; AKT1; TP53; CA1; CA9; ESR1; ESR1; TLR2; NFKB1; MMP2; MCL1; APP; MMP9 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; APP; PPARG; PPARG |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1; AKR1B1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1; HCAR2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; TLR2; TERT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| NA: NA | Menopausal disorder | NA | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PPARG |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; TERT; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH; ESR1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |